1. 229 Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy. (9th November 2020) Authors: Beeler, Kristina; Vowinckel, Jakob; Soste, Martin; Mallardo, Domenico; Capone, Mariaelena; Gabriele, Madonna; Sorrentino, Antonio; Vanella, Vito; Sklodowski, Kamil; Heinzmann, Daniel; Ascierto, Paolo Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 229 Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy. (9th November 2020) Authors: Beeler, Kristina; Vowinckel, Jakob; Soste, Martin; Mallardo, Domenico; Capone, Mariaelena; Gabriele, Madonna; Sorrentino, Antonio; Vanella, Vito; Sklodowski, Kamil; Heinzmann, Daniel; Ascierto, Paolo Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. (March 2020) Authors: Cortellini, Alessio; Bersanelli, Melissa; Santini, Daniele; Buti, Sebastiano; Tiseo, Marcello; Cannita, Katia; Perrone, Fabiana; Giusti, Raffaele; De Tursi, Michele; Zoratto, Federica; Marconcini, Riccardo; Russano, Marco; Zeppola, Tea; Anesi, Cecilia; Filetti, Marco; Marchetti, Paolo; Botticelli... Journal: European journal of cancer Issue: Volume 128(2020) Page Start: 17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. Issue 1 (16th July 2018) Authors: Capone, Mariaelena; Giannarelli, Diana; Mallardo, Domenico; Madonna, Gabriele; Festino, Lucia; Grimaldi, Antonio Maria; Vanella, Vito; Simeone, Ester; Paone, Miriam; Palmieri, Giuseppe; Cavalcanti, Ernesta; Caracò, Corrado; Ascierto, Paolo Antonio Journal: Journal for immunotherapy of cancer Issue: Volume 6:Issue 1(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes. (January 2023) Authors: Lee, Joanna; Ahmed, Tasnia; Maurichi, Andrea; Di Guardo, Lorenzo; Stagno, Anna M.; Warburton, Lydia; Taylor, Amelia. M.; Livingstone, Elisabeth; Rehman, Saba; Khattak, Adnan; Kahler, Katharina C.; Vanella, Vito; Atkinson, Victoria; Millward, Michael; Schadendorf, Dirk; Johnson, Douglas B.; Ascier... Journal: European journal of cancer Issue: Volume 179(2023) Page Start: 87 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. (4th March 2017) Authors: Simeone, Ester; Grimaldi, Antonio Maria; Festino, Lucia; Giannarelli, Diana; Vanella, Vito; Palla, Marco; Curvietto, Marcello; Esposito, Assunta; Palmieri, Giuseppe; Mozzillo, Nicola; Ascierto, Paolo Antonio Journal: Oncoimmunology Issue: Volume 6:Number 3(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Dermatologic adverse events associated with targeted therapies for melanoma. Issue 3 (4th March 2022) Authors: Scarpato, Luigi; Festino, Lucia; Vanella, Vito; Madonna, Gabriele; Mastroianni, Massimo; Palla, Marco; Ascierto, Paolo Antonio Journal: Expert opinion on drug safety Issue: Volume 21:Issue 3(2022) Page Start: 385 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma. (3rd April 2021) Authors: Vanella, Vito; Festino, Lucia; Vitale, Maria Grazia; Alfano, Benedetta; Ascierto, Paolo Antonio Journal: Expert opinion on emerging drugs Issue: Volume 26:Number 2(2021) Page Start: 79 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. Issue 3 (4th March 2019) Authors: Trojaniello, Claudia; Festino, Lucia; Vanella, Vito; Ascierto, Paolo A. Journal: Expert review of clinical pharmacology Issue: Volume 12:Issue 3(2019) Page Start: 259 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts. Issue 1 (January 2017) Authors: Hirsh, Vera; Pignata, Sandro; Bersanelli, Melissa; Gnetti, Letizia; Azzoni, Cinzia; Bottarelli, Lorena; Gasparro, Donatello; Leonardi, Francesco; Silini, Enrico; Buti, Sebastiano; Wennerberg, Erik; Mediero, Aranzazu; Cronstein, Bruce; Formenti, Silvia; Demaria, Sandra; Vanpouille-Box, Claire; Pil... Journal: Journal of translational medicine Issue: Volume 15:Issue 1(2017) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗